Frequently asked questions regarding SARS-CoV2 in cancer patients: Recommendations for clinicians caring for patients with malignant diseases

Authors

Marie von Lilienfeld-Toal1,2, Jörg Janne Vehreschild3,4,5, Oliver Cornely4,5,6,7,13, Livio Pagano6, Francesca Compagno9, Hans H. Hirsch10,11,12

on behalf of the EHA Scientific Working Group Infections in Hematology

1. Jena University Hospital, Department of Hematology and Medical Oncology, Jena, Germany
2. Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll Institute, Jena, Germany
3. Goethe University Frankfurt, Department of Internal Medicine, Hematology/Oncology, Frankfurt, Germany
4. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany
5. German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany
6. University of Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
7. University of Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany
8. Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli (IRCCS), Department of Hematology, Rome, Italy
9. Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
10. University Hospital Basel, Clinical Virology, Laboratory Medicine, Basel, Switzerland
11. University of Basel, Transplantation & Clinical Virology, Department Biomedicine, Basel, Switzerland
12. University Hospital Basel, Infectious Diseases & Hospital Epidemiology, Basel, Switzerland
13. Chair, EHA Infectious Diseases Scientific Working Group

Corresponding author

Prof. Dr. Marie von Lilienfeld-Toal
Klinik für Innere Medizin II, Abteilung für Hämatologie und internistische Onkologie
Universitätsklinikum Jena
Am Klinikum 1, 07747 Jena, Germany
Phone: +49 3641 9-324210, Fax: +49 3641 9-324657
Marie.von_Lilienfeld-Toal@med.uni-jena.de